FREMONT, Calif., Sept. 19, 2016 /PRNewswire/ -- DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, today announced the launch of InCELL Pulse™ target engagement platform that provides scientists with the ability to generate their own cell-based target engagement assays for confirming compound cell entry and target binding in the native cellular environment.
Monitoring cellular drug penetration and drug-target interaction enables assessment of compound on-target potency and confirmation of mode of action. Current platforms on the market for measuring target engagement focus on a limited set of biochemical or cell-based targets. DiscoverX's new InCELL Pulse cellular compound-target engagement platform provides drug discovery scientists the ability to create their own target engagement cell-based assays. With InCELL Pulse one can confirm compound cell entry and target binding, validate hits identified in biochemical assays, measure cellular EC50 values, and rank compound potency – all in the native cellular environment. These simple cellular binding assays require no custom chemical tracer or antibody reagents and provide a convenient, easy-to-use protocol for a target of your choice.
"With the addition of the InCELL Pulse target engagement assays to our current target engagement portfolio, our customers now have complete control to develop their own cell-based binding assays, a capability many researchers need due to the unique compounds and targets that aren't offered by commercially available assays," stated Theresa Schaub, Sr. VP of Commercial Operations for DiscoverX.
InCELL Pulse target engagement assays allow for rapid creation of target engagement cell-based assays in less than 2 weeks after cloning. Todd R. Nelson, Ph.D., CEO of DiscoverX, stated, "Now customers can easily confirm compound cell entry and measure compound binding to their protein target in the native cellular environment even when functional assays are difficult or unavailable. DiscoverX remains committed to providing solutions and platforms for our customers to easily generate biologically relevant data for more confident drug discovery decisions."
For more information on DiscoverX's InCELL Pulse, visit discoverx.com/incell.
DiscoverX Corporation, headquartered in Fremont, CA, USA, is a leader in the design, manufacture and sale of biochemical and cell-based assays for the drug discovery & life science markets. This industry-leading portfolio of products and services, under the KINOMEscan®, PathHunter® and BioMAP® brands, are used to aid life science research and enable rapid development of safe and effective biologic and small molecule drugs, by improving research productivity, effectiveness of screening, lead optimization & bioanalytical campaigns, as well as providing predictive tools that deliver physiologically relevant insights on drug molecules from early discovery through pre-clinical development. DiscoverX embodies an innovative approach to creating life science tools that have been widely adopted across the globe in pharmaceutical, biotechnology and academic laboratories. Learn more at discoverx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/discoverx-launches-cell-based-assays-for-confirmation-of-compound-target-engagement-in-drug-discovery-300329248.html
SOURCE DiscoveRx Corporation